IPO

Creative Graphics Solutions India Limited IPO opens on Thursday, March 28; price band fixed at Rs. 80–85

March 22, 2024 TeluguSuperNews

Telugu super news,Hyderabad, March 22, 2024: Creative Graphics Solutions India Limited (“Creative Graphics” or “The Company”), India’s leading organised and integrated packaging ecosystem player, announced that its initial public offering (IPO) will open on Thursday, March 28, 2024. The anchor portion will be opened on Wednesday, March 27, 2024, and the issue will conclude on Thursday, April 04, 2024. The company intends to raise approximately Rs. 54.4 crore (at upper band) from the offering and aims to be listed with NSE Emerge. The price band for the issue has been fixed at Rs. 80/- – Rs. 85/- per share, and the lot size will be 1,600 equity shares.

Corporate Capital Ventures is the Book Running Lead Manager, and Bigshare Services Private Limited is the Registrar for the issue Private Limited is the Registrar to the issue. Corporate Capital Ventures Private Limited completed a string of successful SME IPOs in recent months, including Alpex Solar, Esconet Technologies, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.

Creative Graphics is a product of the MSMEx SME IPO Cohort program, mentored by Amit Kumar, Founder & CEO at MSMEx.

The Noida-based company’s IPO will comprise a fresh issue of 64,00,000 Equity Shares with a face value of Rs. 10/- through the book-building route. As many as 3.2 lakh equity shares have been reserved for Market Maker, 9.12 lakh equity shares allocated for NIIs, 30.4 lakh equity shares for QIBs (including 18.24 lakh equity shares as Anchor investor portion), and the Retail (RII) portion accounts for 21.28 lakh equity shares.

According to the RHP document, the company intends to utilise net proceeds from the IPO to meet the working capital requirements of the company, repay/prepay, in part or full of certain of the company’s borrowings, meet the capital expenditure of the company, fund inorganic growth through unidentified acquisition for the company, and general corporate expenses.

Creative Graphics specialises in manufacturing flexographic printing plates, including Digital Flexo Plates, Conventional Flexo Printing Plates, Letter Press Plates, Metal Back Plates, and Coating Plates. The company serves its customer base in India, Thailand, Qatar, Kuwait, Nepal, and Africa. It operates seven manufacturing facilities in different states: Noida (Uttar Pradesh), Vasai, Pune (Maharashtra), Chennai (Tamil Nadu), Baddi (Himachal Pradesh), Hyderabad (Telangana), and Ahmedabad (Gujarat).

Founded by Deepanshu Goel, a first-generation entrepreneur and incorporated in 2014, Creative Graphics has expanded its business through its wholly owned subsidiaries – Creative Graphics Premedia Private Limited (CG Premedia) and Wahren India Private Limited. While CG Premedia offers end-to-end premedia services, from design adaptation to print production, Wahren India supplies high-quality packaging solutions for the pharmaceutical industry. It produces Alu-Alu Foil, Blister Foil, Tropical Alu-Alu Foil, CR Foil, and Pharmaceutical Sachet.

The company clocked revenue of Rs. 48.07 crore and earned a profit (PAT) of Rs. 7.24 crore during the first half of the current fiscal year, which ended September 30, 2023. It registered revenue of Rs. 90.14 crore and a profit (PAT) of Rs. 8.64 crore in FY2022-23.

Accent Microcell Limited IPO gets overwhelming response from investors; records 362 times subscription

December 13, 2023 TeluguSuperNews Leave a comment

Telugu super news,Hyderabad, December 13, 2023: The Initial Public Offer (IPO) of Accent Microcell Limited received an overwhelming response from the investors as it recorded 362 times subscription till the final day of bidding. The Ahmedabad-based manufacturer and exporter of pharmaceutical excipients aimed to raise Rs. 78.40 crores from the issue that was floated between December 08 – 12.

Category	No of Equity Shares	Number of shares bid	Subscription (No of Times)
QIB	10,64,000	12,60,62,000	118.48
HNI/NII	7,98,000	46,04,54,000	577.01
RII	18,62,000	76,28,84,000	409.71
Total	37,24,000	1,34,94,00,000	362.35

While the Qualified Institutional Buyer (QIB) portion of the issue was subscribed 119 times, the HNI/NII quota was subscribed 577 times and the Retail Individual Investors (RII) quota was subscribed 410 times, bringing the overall subscription to 362 times till the final day of bidding on Tuesday, December 12, 2023.

The price band of the issue is fixed at Rs. 133-140 per equity share with a face value of Rs. 10 apiece. The IPO comprised of fresh issue of 56 lakh Equity Shares with a face value of Rs. 10/- through the book-building route. The minimum lot size for the application is 1,000 shares. The company is proposed to be listed on NSE Emerge.

Corporate Capital Ventures Private Limited is the Book Running Lead Manager to the issue.

Accent Microcell Limited plans to utilise Rs. 54.39 crores out of net proceeds from the offering to establish a new plant at Navagam Kheda, Gujarat, India, for manufacturing Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG) and Carboxymethylcellulose (CMC), which is expected to be commercialised by April 2025. It plans to use the remaining funds for general corporate purposes.

With the addition of 2,400 metric tonnes to its current annual total installed capacity of 8,000 metric tonnes, the company plans to increase its cumulative annual capacity to 10,400 metric tonnes, including all range of excipients category (including premium excipients products). The expansion of capacity will enable the company to deliver products that are specifically tailored to customer needs. In addition to the existing customer base, the company will cater to clients in untapped regions.

For more information, please visit: www.accentmicrocell.com

Accent Microcell IPO to open on December 8, 2023; fixes a price band of Rs. 133 – Rs. 140 per share

December 4, 2023 TeluguSuperNews Leave a comment

Telugu super news,Hyderabad, December 4, 2023: Accent Microcell Limited, a leading manufacturer and exporter of cellulose-based pharmaceutical excipients, announced, today announced that its Initial Public Offer will open on Friday, December 8, 2023. The Anchor portion will be open on Thursday, December 7, 2023, and the issue will conclude on Tuesday, December 12, 2023. The company is planning to raise approximately Rs. 78.40 crores from the issue and aims to be listed with NSE Emerge. The price band for the issue has been fixed at Rs. 133 – Rs. 140 per share. The lot price will be 1,000 shares. Corporate Capital Ventures Private Limited is the Book Running Lead Manager and KFIN Technologies Limited is the Registrar to the Issue.

The IPO will comprise of fresh issue of 56 lakh Equity Shares with a face value of Rs 10/- through the book-building route. While 15.96 lakh equity shares have been reserved for Anchor portion, 2.8 lakh equity shares for Market Maker, 10.64 lakh equity shares for QIB portion, 7.98 lakh equity shares allocated for NIIs and Retail (RII) portion accounts for 18.62 lakh equity shares.

Accent Microcell plans to utilise Rs. 54.39 crores out of net proceeds from the offering to establish a new plant at Navagam Kheda, Gujarat, India for manufacturing Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG) and Carboxymethylcellulose (CMC), which is expected to be commercialised by April 2025.

The company predominantly manufactures Microcrystalline Cellulose (“MCC”), which is widely used as a texturizer, anticaking agent, binder, lubricant, bulking agent, and diluent with an extensive range of applications in pharmaceutical, nutraceutical, food, cosmetic and other industries. In addition to MCC, it produces other excipients such as Croscarmellose Sodium (CCS) and Magnesium Stearate (MS).

Leveraging its high-quality product line, the company has established a long-standing market in India and abroad. Accent Microcell exports its products to more than 45 countries, including the USA, Canada, Germany and many others.

Incorporated in 2012, Accent Microcell has successfully developed a resilient manufacturing infrastructure, supported by an efficient supply chain that caters to the needs of various Indian and global customers. With two state-of-the-art manufacturing facilities located in Pirana (Unit-I), and Dahej SEZ (Unit-II), the company serves various categories of clients from different industries. With the addition of 2,400 metric tonnes to its current annual total installed capacity of 8,000 metric tonnes, the company plans to increase its cumulative annual capacity to 10,400 metric tonnes including all range of excipients category (including premium excipients products). The expansion of capacity will enable the company to deliver products that are specifically tailored to customer needs. In addition to existing customer base, the company will cater to the clients in untapped regions.

Accent Microcell registered a revenue of Rs. 204.19 Cr. in FY23, up from INR 165.71 crore in FY22. In the first quarter of FY24, ending June 30, the company clocked a revenue of Rs. 58.81 crore. Accent Microcell’s profit (PAT) more than doubled to Rs. 13.01 crore in FY23 from Rs. 5.89 crore in FY22. The company achieved Profit After Tax (PAT) of Rs. 7.06 crore in Q1 of FY2023-24.

For more information, please visit: www.accentmicrocell.com

Sunrest Lifescience Ltd plans to raise up to Rs. 10.85 crore from public issue; IPO opens Nov 7-based Pharmaceutical company

November 7, 2023 TeluguSuperNews Leave a comment

Telugu super news,Ahmedabad, November 7th,2023: Ahmedabad-based Pharmaceutical company, Sunrest Lifescience Ltd is planning to raise Rs. 10.85 crore from its SME public issue. The public issue opens for subscription on November 7. The company has received approval to launch its public issue on NSE Emerge Platform of National Stock Exchange. Proceeds of the public issue will be utilised to fund company’s expansion plans including meeting working capital requirements and General Corporate purpose. Mark Corporate Advisors Private Limited is the lead manager of the issue. Public issue will close on November 09.

The initial public offering comprises of a fresh issue of 12.91 lakh equity shares of face value Rs. 10 each at a price of Rs. 84 per share (including a premium of Rs. 74 per equity share) aggregating up to Rs. 10.85 crore. Minimum lot size for the application is 1,600 shares which translates in to investment of Rs. 1.34 lakh per application. Retail allocation for the IPO is kept each at 50% of the issue. Market maker reservation portion is 65,600 equity shares.

Incorporated in 2017, Sunrest Lifescience Limited offers a diverse range of healthcare and personal care products. The company’s product range includes Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste. Sunrest Lifescience’s product portfolio encompasses an extensive range of drugs such as Anti-Bacterial, AntiDiarrheal, AntiFungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-inflammatory.

With 18 Registered Trademarks for 32 products, Sunrest Lifescience is committed to delivering high-quality products to its customers. The company gets its products manufactured by third-party pharma product manufacturers which also includes Trilend Pharmaceuticals Pvt Ltd (Trilend), a Sunrest group company. The company has various third-party manufacturers across these states: Gujarat, Punjab, Maharashtra, Haryana, Himachal Pradesh, Uttarakhand and Madhya Pradesh.

Mr. Nikhilkumar Thakkar, Mr. Amitbhai Thakkar, Mr. Bhagyesh Parekh and Mr. Bharatkumar Thakkar are the promoters of the company. Promoter holding post-issue will be 69.91%.

For the FY22-23 company reported total revenue of Rs. 24.67 crore and Net Profit of Rs. 2.04 crore. As on 30 June 2023, Reserves & Surplus stands at Rs. 86.60 lakh, Total Assets at Rs. 17.06 crore and Net Worth of Rs. 3.86 crore. Shares of the company will be listed on NSE’s Emerge platform.

IPO Highlights – Sunrest Lifescience Ltd
IPO Opens on	November 7, 2023
IPO Closes on	November 9, 2023
Issue Price	Rs. 84 Per Share
Issue Size (No of Shares)	1,291,200 Shares
Issue Size (Rs. Cr)	Rs. 10.85 crore
Lot Size	1,600 Shares
Listing on	NSE Emerge Platform of National Stock Exchange